Author

M. A. Ligtenberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. de Bruijn· 2 shared D. S. Peeper· 2 shared D. W. Vredevoogd· 2 shared J. Boshuizen· 2 shared O. Krijgsman· 2 shared A. Shahrabi· 1 shared C. U. Blank· 1 shared D. D'Empaire Altimari· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. de Bruijn

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology

LOSS OF UBIQUITIN LIGASE STUB1 AMPLIFIES IFNγ-R1/JAK1 SIGNALING AND SENSITIZES TUMORS TO IFNγ

G. Apriamashvili, D. W. Vredevoogd, O. Krijgsman, O. B. Bleijerveld, M. A. Ligtenberg, B. de Bruijn, J. Boshuizen, D. D'Empaire Altimari, N. L. Visser, J. D. Londino, M. Altelaar, D. S. Peeper

This study shows that loss of STUB1 enhances IFNγ signaling and sensitizes tumors to IFNγ, suggesting STUB1 inhibition combined with PD-1 blockade could improve cancer immunotherapy.

bioRxiv · Jul 7, 2020 · PreprintCancer Biology